Advertisement
Advertisement

NRIX

NRIX logo

Nurix Therapeutics, Inc. Common stock

17.12
USD
Sponsored
+0.60
+3.63%
Feb 02, 14:12 UTC -5
Open

NRIX Earnings Reports

Positive Surprise Ratio

NRIX beat 10 of 22 last estimates.

45%

Next Report

Date of Next Report
Apr 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$16.94M
/
-$0.84
Implied change from Q4 25 (Revenue/ EPS)
+24.74%
/
+2.44%
Implied change from Q1 25 (Revenue/ EPS)
-8.20%
/
+25.37%

Nurix Therapeutics, Inc. Common stock earnings per share and revenue

On Jan 28, 2026, NRIX reported earnings of -0.82 USD per share (EPS) for Q4 25, beating the estimate of -0.88 USD, resulting in a 7.66% surprise. Revenue reached 13.58 million, compared to an expected 14.60 million, with a -6.96% difference. The market reacted with a +3.52% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -0.84 USD, with revenue projected to reach 16.94 million USD, implying an increase of 2.44% EPS, and increase of 24.74% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
FAQ
For Q4 2025, Nurix Therapeutics, Inc. Common stock reported EPS of -$0.82, beating estimates by 7.66%, and revenue of $13.58M, -6.96% below expectations.
The stock price moved up 3.52%, changed from $18.75 before the earnings release to $19.41 the day after.
The next earning report is scheduled for Apr 06, 2026.
Based on 10 analysts, Nurix Therapeutics, Inc. Common stock is expected to report EPS of -$0.84 and revenue of $16.94M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement